Special Issue "Virus-Like Particle (VLP) Vaccines against Emerging Infectious Diseases"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".

Deadline for manuscript submissions: 31 January 2024 | Viewed by 233

Special Issue Editor

Department of Pharmacology, University of Minnesota Twin Cities, Saint Paul, MN 55108, USA
Interests: coronavirus; antibody; crystal structure; viral entry and replication
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Emerging Infectious Diseases (EIDs) have been threatening human and animal health, causing damage to the global economy and the stability of society. Against the background of a growing human population, globalization, and more active human behavior around the world, EIDs have more opportunities to spread from animals to humans and transmit more efficiently among the latter, which may cause epidemics or even pandemics. Since 1940, many EID events have been reported, such as West Nile fever, Lassa fever, Ebola hemorrhagic fever, AIDS, and flu. In particular, coronavirus has shocked the world three times in the past 20 years, with the SARS strain in 2002, MERS in 2012 and COVID-19 since 2019. One of the most important strategies to prevent/treat EIDs is vaccination. Virus-Like Particle (VLP) based vaccines are a novel strategy to develop effective vaccines and show advantages over conventional vaccines. As subunit vaccines, they are safer than some conventional vaccines. VLPs better represent antigens on their surface, have high immunogenicity, and are capable of inducing both strong humoral and cellular immune responses. With their unique characteristics, VLP vaccines will play an important role in combating EIDs in the future. 

This Special Issue welcomes studies (research articles and brief reports) focused on Virus-Like Particle (VLP) vaccines against emerging infectious diseases, including those caused by viruses, bacteria, parasites, and other pathogens from either humans or animals.

Dr. Gang Ye
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Emerging Infectious Diseases (EIDs)
  • Virus-Like Particle (VLP)

Published Papers

This special issue is now open for submission.
Back to TopTop